LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Your last searches

  1. AU="Kakkar, Ashish Kumar"
  2. AU=Lee Jung-Mi
  3. AU="Tartaglia, Elena"

Search results

Result 1 - 10 of total 54

Search options

  1. Article ; Online: Editorial: Antimicrobial resistance and stewardship in the COVID-19 era.

    Kakkar, Ashish Kumar / Shafiq, Nusrat

    Frontiers in public health

    2024  Volume 12, Page(s) 1398981

    MeSH term(s) Humans ; Antimicrobial Stewardship ; COVID-19 ; SARS-CoV-2 ; Anti-Bacterial Agents/therapeutic use ; Drug Resistance, Microbial ; COVID-19 Drug Treatment
    Language English
    Publishing date 2024-05-01
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2711781-9
    ISSN 2296-2565 ; 2296-2565
    ISSN (online) 2296-2565
    ISSN 2296-2565
    DOI 10.3389/fpubh.2024.1398981
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Pharmaceutical price regulation and its impact on drug innovation: mitigating the trade-offs.

    Kakkar, Ashish Kumar

    Expert opinion on therapeutic patents

    2021  Volume 31, Issue 3, Page(s) 189–192

    MeSH term(s) Drug Costs/legislation & jurisprudence ; Economics, Pharmaceutical ; Health Care Costs/legislation & jurisprudence ; Humans ; Patents as Topic ; Pharmaceutical Preparations/economics
    Chemical Substances Pharmaceutical Preparations
    Language English
    Publishing date 2021-02-10
    Publishing country England
    Document type Editorial
    ZDB-ID 1186201-4
    ISSN 1744-7674 ; 0962-2594 ; 1354-3776
    ISSN (online) 1744-7674
    ISSN 0962-2594 ; 1354-3776
    DOI 10.1080/13543776.2021.1876029
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Field based research in the era of the pandemic in resource limited settings: challenges and lessons for the future.

    Mulchandani, Rubina / Lyngdoh, Tanica / Gandotra, Sheetal / Isser, H S / Dhamija, Rajinder K / Kakkar, Ashish Kumar

    Frontiers in public health

    2024  Volume 12, Page(s) 1309089

    Abstract: The coronavirus pandemic that began in December 2019, has had an unprecedented impact on the global economy, health systems and infrastructure, in addition to being responsible for significant mortality and morbidity worldwide. The "new normal" has ... ...

    Abstract The coronavirus pandemic that began in December 2019, has had an unprecedented impact on the global economy, health systems and infrastructure, in addition to being responsible for significant mortality and morbidity worldwide. The "new normal" has brought along, unforeseen challenges for the scientific community, owing to obstructions in conducting field-based research in lieu of minimizing exposure through in-person contact. This has had greater ramifications for the LMICs, adding to the already existing concerns. As a response to COVID-19 related movement restrictions, public health researchers across countries had to switch to remote data collections methods. However, impediments like lack of awareness and skepticism among participants, dependence on paper-based prescriptions, dearth of digitized patient records, gaps in connectivity, reliance on smart phones, concerns with participant privacy at home and greater loss to follow-up act as hurdles to carrying out a research study virtually, especially in resource-limited settings. Promoting health literacy through science communication, ensuring digitization of health records in hospitals, and employing measures to encourage research participation among the general public are some steps to tackle barriers to remote research in the long term. COVID-19 may not be a health emergency anymore, but we are not immune to future pandemics. A more holistic approach to research by turning obstacles into opportunities will not just ensure a more comprehensive public health response in the coming time, but also bolster the existing infrastructure for a stronger healthcare system for countries.
    MeSH term(s) Humans ; Pandemics/prevention & control ; COVID-19/epidemiology ; Communication ; Developing Countries ; Health Literacy
    Language English
    Publishing date 2024-02-29
    Publishing country Switzerland
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 2711781-9
    ISSN 2296-2565 ; 2296-2565
    ISSN (online) 2296-2565
    ISSN 2296-2565
    DOI 10.3389/fpubh.2024.1309089
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Patent cliff mitigation strategies: giving new life to blockbusters.

    Kakkar, Ashish Kumar

    Expert opinion on therapeutic patents

    2015  Volume 25, Issue 12, Page(s) 1353–1359

    Abstract: With several blockbuster drugs on the brink of another significant patent expiry cliff, innovator pharmaceutical firms are at risk of losing billions of dollars in sales to generic competition. With issues such as staggering R&D costs, reduced ... ...

    Abstract With several blockbuster drugs on the brink of another significant patent expiry cliff, innovator pharmaceutical firms are at risk of losing billions of dollars in sales to generic competition. With issues such as staggering R&D costs, reduced productivity and increasing governmental emphasis on pharmacoeconomics, timely planning and implementation of product lifecycle management strategies is becoming indispensable. A variety of strategies designed to mitigate the post-patent expiry revenue loss exist. These approaches range from fairly straightforward measures, such as strategic price cuts and launching own or authorized generics, to complex and lengthy ones, such as new formulations and indications that require companies to reinvent their pharmaceuticals. As patent expiries loom and product pipelines continue to remain thin, proactive planning for generic entry will be critical for pharma companies to drive growth and earnings in a sustainable manner.
    MeSH term(s) Commerce/economics ; Drug Costs ; Drug Industry/economics ; Drugs, Generic/economics ; Economic Competition/economics ; Economics, Pharmaceutical ; Efficiency, Organizational/economics ; Humans ; Patents as Topic ; Research/economics
    Chemical Substances Drugs, Generic
    Language English
    Publishing date 2015
    Publishing country England
    Document type Editorial
    ZDB-ID 1186201-4
    ISSN 1744-7674 ; 0962-2594 ; 1354-3776
    ISSN (online) 1744-7674
    ISSN 0962-2594 ; 1354-3776
    DOI 10.1517/13543776.2015.1088833
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: India puts informed consent on camera.

    Kakkar, Ashish Kumar

    Science (New York, N.Y.)

    2014  Volume 344, Issue 6180, Page(s) 150–151

    MeSH term(s) Clinical Trials as Topic/legislation & jurisprudence ; Consent Forms/legislation & jurisprudence ; Humans ; India ; Video Recording/legislation & jurisprudence
    Language English
    Publishing date 2014-04-11
    Publishing country United States
    Document type Letter
    ZDB-ID 128410-1
    ISSN 1095-9203 ; 0036-8075
    ISSN (online) 1095-9203
    ISSN 0036-8075
    DOI 10.1126/science.344.6180.150-b
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: GLP-1 receptor agonists and the risk of colorectal cancer.

    Kakkar, Ashish Kumar

    Medical hypotheses

    2014  Volume 82, Issue 6, Page(s) 796

    MeSH term(s) Colorectal Neoplasms/physiopathology ; Humans ; Receptors, Glucagon/agonists
    Chemical Substances Receptors, Glucagon
    Language English
    Publishing date 2014-06
    Publishing country United States
    Document type Comment ; Letter
    ZDB-ID 193145-3
    ISSN 1532-2777 ; 0306-9877
    ISSN (online) 1532-2777
    ISSN 0306-9877
    DOI 10.1016/j.mehy.2014.03.028
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Reporting of adverse drug reactions in India: A review of the current scenario, obstacles and possible solutions.

    Mulchandani, Rubina / Kakkar, Ashish Kumar

    The International journal of risk & safety in medicine

    2018  Volume 30, Issue 1, Page(s) 33–44

    Abstract: Pharmacovigilance is a practice aimed to monitor drug safety in real life conditions and capture adverse drug events during the post marketing phase of drug's life cycle. But under reporting of adverse reactions is a major cause of concern and a threat ... ...

    Abstract Pharmacovigilance is a practice aimed to monitor drug safety in real life conditions and capture adverse drug events during the post marketing phase of drug's life cycle. But under reporting of adverse reactions is a major cause of concern and a threat to the pharmacovigilance systems. The present article looks into the major obstacles affecting the spontaneous reporting of adverse drug reactions (ADRs) in India and the possible solutions. As per available scientific literature, the major impediments to ADR reporting are inadequate knowledge and awareness among health professionals, clinicians' perceptions towards reporting, problems with establishing reporting systems in hospitals and insufficient training to recognize ADRs. Measures to improve the situation include greater involvement of nurses, pharmacists as well as consumers in the reporting of ADRs, making the process simpler and faster through electronic means, introducing educational interventions and training programs for health care providers and spreading awareness about the reporting system amongst caregivers and receivers alike. Providing a momentum to the pharmacovigilance system and ensuring a robust reporting process is a challenge but proper planning, feasible solutions and focussed efforts can help bring about the change ensuring patient safety - the ultimate goal of pharmacovigilance.
    MeSH term(s) Adult ; Adverse Drug Reaction Reporting Systems/statistics & numerical data ; Attitude of Health Personnel ; Drug-Related Side Effects and Adverse Reactions ; Female ; Health Knowledge, Attitudes, Practice ; Health Personnel/psychology ; Humans ; India ; Male ; Mandatory Reporting ; Middle Aged ; Pharmacists/psychology ; Pharmacovigilance ; Risk Management/statistics & numerical data ; Surveys and Questionnaires
    Language English
    Publishing date 2018-09-03
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 1055458-0
    ISSN 1878-6847 ; 0924-6479
    ISSN (online) 1878-6847
    ISSN 0924-6479
    DOI 10.3233/JRS-180025
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Gender Differences and Evidence-Based Medicine: Navigating the Wide Knowledge Gap.

    Gamad, Nanda / Patil, Amol N / Kakkar, Ashish Kumar

    American journal of therapeutics

    2020  

    Language English
    Publishing date 2020-10-01
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1280786-2
    ISSN 1536-3686 ; 1075-2765
    ISSN (online) 1536-3686
    ISSN 1075-2765
    DOI 10.1097/MJT.0000000000001263
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Cefazolin Shortages in the Developing World: The Same, But Different Too.

    Kakkar, Ashish Kumar / Shafiq, Nusrat / Malhotra, Samir

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

    2020  Volume 72, Issue 7, Page(s) 1293–1295

    MeSH term(s) Cefazolin ; Humans ; Japan
    Chemical Substances Cefazolin (IHS69L0Y4T)
    Language English
    Publishing date 2020-08-13
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 1099781-7
    ISSN 1537-6591 ; 1058-4838
    ISSN (online) 1537-6591
    ISSN 1058-4838
    DOI 10.1093/cid/ciaa847
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Efficacy of anifrolumab in systemic lupus erythematosus: a critical analysis of the TULIP trials.

    Gamad, Nanda / Kakkar, Ashish Kumar / Pattanaik, Smita

    Lupus

    2020  Volume 29, Issue 8, Page(s) 1002–1003

    MeSH term(s) Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Humans ; Lupus Erythematosus, Systemic ; Tulipa
    Chemical Substances Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; anifrolumab (38RL9AE51Q)
    Language English
    Publishing date 2020-06-03
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 1154407-7
    ISSN 1477-0962 ; 0961-2033
    ISSN (online) 1477-0962
    ISSN 0961-2033
    DOI 10.1177/0961203320928425
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top